Evidence map›Paper›PMID 41938648›Full record

ArticleThe World Allergy Organization journal2026

Indication for biologic treatment in a real-world cohort of chronic rhinosinusitis patients according to international recommendations: Evidence from the European CRS outcome registry (CHRINOSOR).

Sven F Seys, Josje J Otten, Joost de Kinderen, Giulia Bettio, Alexandros Andrianakis, Isam Alobid, Carlo Cavaliere, Peter W Hellings, Laura Van Gerven, Valérie Hox and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Sven F SeysGalenus Health (part of Cascador Health), Belgium.
Josje J OttenDepartment of Otorhinolaryngology, Amsterdam University Medical Centres (AUMC), location AMC, Amsterdam, the Netherlands.
Joost de KinderenGalenus Health (part of Cascador Health), Belgium.
Giulia BettioGalenus Health (part of Cascador Health), Belgium.
Alexandros AndrianakisDepartment of General ORL, Head and Neck Surgery, Medical University of Graz, Graz, Austria.
Isam AlobidRhinology Unit & Smell Clinic and Skull Base Surgery Unit, Otorhinolaryngology Department, Hospital Clinic Barcelona, Universitat de Barcelona, IDIBAPS, CIBERES, Barcelona, Catalonia, Spain.
Carlo CavaliereDepartment of Sense Organs, Sapienza University, Rome, Italy.
Peter W HellingsDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.
Laura Van GervenDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.
Valérie HoxService d'Otorhinolaryngologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Claire HopkinsENT Department, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Anette KjeldsenDepartment of Otorhinolaryngology, Odense University Hospital, Odense, Denmark.
Sven SchneiderDepartment of Otorhinolaryngology, Head and Neck Surgery, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria.
Peter-Valentin TomazicDepartment of General ORL, Head and Neck Surgery, Medical University of Graz, Graz, Austria.
Zuzana DiamantAllergy and Clinical Immunology Research Group, Department of Microbiology, Immunology & Transplantation, KU Leuven, Belgium.
Julia Eckl-DornaDepartment of Otorhinolaryngology, Head and Neck Surgery, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria.
Wytske J FokkensDepartment of Otorhinolaryngology, Amsterdam University Medical Centres (AUMC), location AMC, Amsterdam, the Netherlands.
Clemens HolzmeisterDepartment of General ORL, Head and Neck Surgery, Medical University of Graz, Graz, Austria.
Kenneth LarsenDepartment of Otorhinolaryngology, Odense University Hospital, Odense, Denmark.
Anu Laulajainen-HongistoDepartment of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Finland.
Valerie LundDepartment of Rhinology, Royal National Ear, Nose, Throat and Eastman Dental Hospital, UCLH, United Kingdom.
Gert MariënGalenus Health (part of Cascador Health), Belgium.
Simonetta MasieriDepartment of Oral and Maxillofacial Sciences, Sapienza University, Rome, Italy.
Geoffrey MortuaireOtorhinolaryngology-Head and Neck Department, Huriez Hospital, Centre Hospitalier Universitaire (CHU) Lille, Lille, France.
Mathilde MoyaertDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.
Joaquim MullolRhinology Unit & Smell Clinic and Skull Base Surgery Unit, Otorhinolaryngology Department, Hospital Clinic Barcelona, Universitat de Barcelona, IDIBAPS, CIBERES, Barcelona, Catalonia, Spain.
Camilo Rodriguez van StrahlenRhinology Unit & Smell Clinic and Skull Base Surgery Unit, Otorhinolaryngology Department, Hospital Clinic Barcelona, Universitat de Barcelona, IDIBAPS, CIBERES, Barcelona, Catalonia, Spain.
Marco de VincentiisDepartment of Sense Organs, Sapienza University, Rome, Italy.
Martin WagenmannDepartment of Otorhinolaryngology, Universitätsklinikum Düsseldorf (UKD), Dusseldorf, Germany.
Sietze ReitsmaDepartment of Otorhinolaryngology, Amsterdam University Medical Centres (AUMC), location AMC, Amsterdam, the Netherlands.
Claus BachertClinic for ENT diseases and Head and Neck Surgery, University Clinic Münster, Münster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In recent years, treatment options for patients with uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) have been expanded with biologics. Definitions of uncontrolled severe disease differ across international recommendations and the prescription of biologics depends on national reimbursement criteria. Objective: We aimed to evaluate the indication for biologic treatment, based on international recommendations, in a real-world cohort of CRSwNP patients. Methods: CRS patients who visited the outpatient ENT clinic of 10 tertiary centres from 7 European countries were invited to use the Galenus Health mobile application monitoring their disease. The proportion of patients who fulfilled biologic indication criteria according to EUFOREA 2021 and EPOS/EUFOREA 2023 recommendations was evaluated. Results: A total of 281 CRS patients were recruited of which 227 (82.1%) were diagnosed as CRSwNP. Out of these 227 patients, 21 patients with prior biologic use were excluded, resulting in a cohort of 206 patients. A total of 28.7% (50/174) and 47.6% (81/170) of CRSwNP patients, met the EUFOREA 2021 or EPOS/EUFOREA 2023 criteria for indication for biologic treatment, respectively. Biologic treatment was initiated at the time of inclusion in the cohort in 18.9% (39/206) of CRSwNP patients. Conclusion: According to international recommendations, 29-48% of CRSwNP patients in tertiary centres may be a candidate for biologic treatment. EPOS/EUFOREA2023 criteria were more inclusive than EUFOREA 2021 criteria with respect to biologic indication for CRSwNP. National reimbursement criteria prevail over international recommendations for actual biologic prescription and are less restrictive in some countries.

Indexed as

biologicChronic rhinosinusitisIndicationnasal polypsReal-world evidence

Identifiers

PMID41938648
PMCPMC13045673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.